ABFL - ETF AI Analysis
Top Page
FCF US Quality ETF (ABFL)
ABFL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 465.93M
- Region
- North America
- Expense Ratio
- 0.49%
- Beta
- 0.96
- Issuer
- Abacus
- Inception Date
- Sep 27, 2016
- Dividend Yield
- 0.60%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
ABFL Summary
ABFL, the Fcf US Quality ETF, invests in a wide range of U.S. companies with strong finances and steady free cash flow, rather than tracking a specific index. It focuses on “quality” businesses across the whole market, from large to small companies. Big names like Apple and Nvidia are among its top holdings, along with major health care and industrial firms. Someone might invest in ABFL to get diversified exposure to many solid U.S. companies in one fund, aiming for long-term growth. A key risk is that it is heavily tilted toward U.S. stocks and tech, so its value can rise and fall with those parts of the market.
How much will it cost me?
This ETF has an expense ratio of 0.49%, which means you’ll pay about $4.90 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because this fund is actively managed and focuses on selecting high-quality companies rather than simply tracking a broad market index.
What would affect this ETF?
ABFL could benefit if the U.S. economy stays healthy, interest rates stabilize or fall, and demand remains strong for technology and health care leaders like Apple, Nvidia, and Eli Lilly, since the fund focuses on financially solid U.S. companies across the total market. On the other hand, higher interest rates, tighter regulations on big tech or drug makers, or a broad U.S. market downturn could hurt its performance, especially given its heavy tilt toward technology and health care and its full reliance on the U.S. market.
ABFL Top 10 Holdings
ABFL leans heavily into U.S. tech and health care, with Apple and Nvidia setting the tone. Apple has been steadily rising, giving the fund a reliable Big Tech engine, while Nvidia’s more mixed, recently lagging performance adds some bumpiness despite its AI-driven story. On the health care side, Eli Lilly, AbbVie, and Gilead are all climbing, acting like a strong defensive line that’s quietly boosting returns. GE Vernova and Bristol-Myers are more mixed, occasionally losing steam, but overall the fund’s U.S.-only, quality-focused tilt is paying off.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AAPL | Apple | 5.85% | $27.28M | $5.03T | 26.98% | 79Outperform |
 NVDA | Nvidia | 4.89% | $22.80M | $4.93T | 0.86% | 76Outperform |
 GEV | GE Vernova Inc. | 3.62% | $16.86M | $227.06B | 49.44% | 69Neutral |
 LLY | Eli Lilly & Co | 3.56% | $16.59M | $1.33T | 67.86% | 72Outperform |
 ABBV | AbbVie | 3.33% | $15.51M | $521.11B | 29.22% | 66Neutral |
 GILD | Gilead Sciences | 3.25% | $15.15M | $211.64B | 44.11% | 78Outperform |
 MA | Mastercard | 2.96% | $13.81M | $559.19B | 15.23% | 75Outperform |
 PANW | Palo Alto Networks | 2.59% | $12.08M | $299.56B | 67.62% | 73Outperform |
 BMY | Bristol-Myers Squibb | 2.73% | $12.71M | $127.71B | 36.96% | 78Outperform |
 V | Visa | 2.64% | $12.29M | $782.42B | 19.87% | 70Outperform |
ABFL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABFL, the sentiment is Negative. The current price of 79.29 is below the 20-day moving average (MA) of 80.32, below the 50-day MA of 80.83, and above the 200-day MA of 78.59, indicating a neutral trend. The MACD of -0.40 indicates Negative momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 64.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABFL.
ABFL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ABFL | $79.29 | $90.00(13.51% Upside) | $465.93M | 0.49% | 73Outperform |
 SEUS | $25.65 | $30.94(20.62% Upside) | $946.37M | 0.30% | 73Outperform |
 BGDV | $31.27 | $37.25(19.11% Upside) | $877.55M | 0.45% | 74Outperform |
 AAUB | $49.94 | $60.90(21.95% Upside) | $845.51M | 0.10% | 66Neutral |
 AVTM | $53.85 | $64.49(19.75% Upside) | $779.89M | 0.22% | 60Neutral |
 XCHG | $27.13 | $33.33(22.85% Upside) | $716.83M | 0.50% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ABFL | FCF US Quality ETF | 79.29 | 7.62 | 10.64% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.65 | 0.39 | 1.53% | |
| BGDV | Bahl & Gaynor Dividend ETF | 31.27 | 5.03 | 19.16% | |
| AAUB | Alpha Architect US Equity 4 ETF | 49.94 | 0.45 | 0.91% | |
| AVTM | Avantis Total Equity Markets ETF | 53.85 | 4.21 | 8.47% | |
| XCHG | AB US Equity ETF | 27.13 | 2.28 | 9.18% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.